Merck Millipore Introduces New Excipient for Solubility/Bioavailability Enhancement - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Merck Millipore Introduces New Excipient for Solubility/Bioavailability Enhancement

Merck Millipore, the life-science division of Merck, has developed a new solubility/bioavailability enhancement excipient, Parteck SLC, which has a unique pore structure that enables higher loading of amorphous APIs, thereby, improving dissolution rates and increasing drug solubility.

Parteck SLC’s mesopores (2–7 nm) create a surface area of up to 1000 m2/g for depositing an API in its amorphous form needed for supersaturation. The internal surface area of Parteck SLC is also easily accessible and the API is kept stable. A user-friendly particle size (5–25 μm) and bulk density (0.32 g/ml) allow easy loading, tableting, or capsule creation.

Parteck SLC is not a novel excipient. Regulatory requirements, therefore, remain the same as it conforms to the silica monographs of Ph Eur and USP. Parteck SLC comes with ready-to-use documentation in CTD-format. Feasibility studies on loading and in vitro dissolution are also available.

Matthias Bucerius, PhD, head of pharmaceutical raw materials, commented in a press statement, that many promising drug candidates fail to get pass the development hurdle because of poor bioavailability and this problem causes significant loss of time and resources to companies. The addition of Parteck SLC to Merck Millipore’s portfolio of excipients provides drug developers with a new option to increase the solubility/bioavailability of their APIs or reformulate their drugs to extend product lifecycle.

Source: Merck Millipore


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here